
Yamo Pharma Presents Statistically Significant Phase 2 Autism Results for L1-79 at INSAR 2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to treating the core symptoms of autism spectrum disorder (ASD), today announced positive Phase 2 results for L1-79, presented at the …